Adaptation process and psychosocial resources of Chinese colorectal cancer patients undergoing adjuvant treatment: a qualitative analysis

2008 ◽  
Vol 18 (9) ◽  
pp. 936-944 ◽  
Author(s):  
Wai Kai Hou ◽  
Wendy W. T. Lam ◽  
Richard Fielding
Keyword(s):  
Colorectal Cancer ◽  
Qualitative Analysis ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Adaptation Process ◽  
Psychosocial Resources ◽  
Colorectal Cancer Patients

Adjuvant treatment in extreme elderly patients with colorectal cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 784-784
Author(s):  
Marta Llopis Cuquerella ◽  
Maria del Carmen Ors Castaño ◽  
María Ballester Espinosa ◽  
Alejandra Magdaleno Cremades ◽  
Vicente Boix Aracil ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
Elderly Patients ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Stage Ii ◽  
Stage Iii ◽  
Complementary Treatment ◽  
Colorectal Cancer Patients

784 Background: Surgical and adjuvant treatment in extreme elderly ( > 80 years) patients with localized colorectal cancer is an unresolved issue. Owing to the lack of available neither clinical practice nor investigational data in this field we present our experience in this scenario. Methods: We retrospectively reviewed data regarding surgical and complementary treatment for colorectal cancer patients aged more than 80 consecutively attended by General Surgery Department in Vega Baja Hospital between 2008 and 2013. Results: A total number of 115 colorectal cancer patients were registered. 95 patients diagnosed of localized disease were selected for analysis. Colon vs rectal cancer ratio was 4:1. Median age was 83.6 years (80-94). Male sex was predominant (60 patients, 63.2%). Emergency surgery was performed in 15 patients (15.8%). Complementary treatment to surgery was advised, according to international guidelines, in 53 patients (55.8%). 10 patients (18.9%) with an advise of adjuvant treatment finally received it. More patients with rectal cancer received recommended treatment (41.7% rectal vs 12.2% colon cancer). Patients with stage III disease were more frequently finally treated according to guidelines (22.2 % stage III vs 11.8% stage II). More patients with stage II rectal cancer were advised and received treatment (recommendation: 66.7% rectal vs 36.1% colon cancer; administration: 25% rectal vs 7.7% colon cancer). Treatment was also more frequently administered to stage III rectal cancer (50% rectal vs 14.3% rectal cancer) (Table). Conclusions: Our experience in localized colorectal cancer in extreme elderly patients ( > 80 years) showed that, although advised according to guidelines, most of them did not receive adjuvant treatment to surgery. Complementary treatment administration was more common in rectal cancer patients and with more advanced disease. [Table: see text]

Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment

2006 ◽  
Vol 24 (10) ◽  
pp. 1603-1611 ◽  
Author(s):  
Emma Dotor ◽  
Miriam Cuatrecases ◽  
María Martínez-Iniesta ◽  
Matilde Navarro ◽  
Felip Vilardell ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Thymidylate Synthase ◽  
Allelic Loss ◽  
Strong Linkage Disequilibrium ◽  
Prognostic Information ◽  
Primary Tumors ◽  
Colorectal Cancer Patients

Purpose The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment. Patients and Methods One hundred twenty-nine colorectal cancer patients homogeneously treated with FU plus levamisole or leucovorin in the adjuvant setting were included. TS enhancer region, 3R G > C single nucleotide polymorphism (SNP), and TS 1494del6 polymorphisms were assessed in both fresh-frozen normal mucosa and tumor. Mutational analyses of TS and allelic imbalances were studied in all primary tumors and in 18 additional metachronic metastases. TS protein immunostaining was assessed in an expanded series of 214 tumors. Multivariate Cox models were adjusted for stage, differentiation, and location. Results Tumor genotyping (frequency of allelic loss, 26%) showed that the 3R/3R genotype was associated with a better outcome (hazard ratio [HR] = 0.38; 95% CI, 0.16 to 0.93; P = .020 for the recessive model). 3R G > C SNP genotyping did not add prognostic information. Tumor TS 1494del6 allele (frequency of allelic loss, 36%) was protective (for each allele with the deletion, based on an additive model, HR = 0.42; 95% CI, 0.22 to 0.82; P = .0034). Both polymorphisms were in strong linkage disequilibrium (D' = 0.71, P < .001), and the 3R/–6 base pair (bp) haplotype showed a significant overall survival benefit compared with the most prevalent haplotype 2R/+6bp (HR = 0.42; 95% CI, 0.20 to 0.85; P = .017). No TS point mutation was detected in primary tumors or metastases. TS protein immunostaining was not associated with survival or any of the genotypes analyzed. Conclusion Tumor TS 1494del6 genotype may be a prognostic factor in FU-based adjuvant treatment of colorectal cancer patients.

Associations of daily partner responses with fatigue interference and relationship satisfaction in colorectal cancer patients.

2018 ◽  
Vol 37 (11) ◽  
pp. 1015-1024
Author(s):  
Fabiola Müller ◽  
Marrit A. Tuinman ◽  
Ellen Stephenson ◽  
Ans Smink ◽  
Anita DeLongis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Relationship Satisfaction ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

Safety and Quality of Life in the Treatment of Non-metastasic Colorectal Cancer Patients: 5-fluorouracil Versus Capecitabine

2019 ◽  
Author(s):  
Julia Sánchez-Gundín ◽  
Cristina Martín-Sabroso ◽  
Ana M. Fernández-Carballido ◽  
D. Barreda-Hernández ◽  
Ana I. Torres-Suárez
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Cancer Patients ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document